Events

Rna Diagnostics Inc. has developed a real-time cancer chemotherapy guidance tool. Less than 25% of breast cancer chemotherapy patients derive survival benefit from chemotherapy. All patients endure toxic effects. Reduction of unnecessary chemotherapy is a top priority for breast cancer specialists. The RNA Disruption Assay (RDA™) is the only diagnostic tool that measures, early in treatment, how a patient is responding to chemotherapy. Administered during the first three cycles, RDA™ measures chemotherapy effectiveness. Effective therapy is confirmed for responding patients, while non-responders may be switched from chemotherapy to alternate therapies, thereby sparing them toxic side effects. RDA™ improves patient outcomes while lowering breast cancer treatment costs.